Xilio Therapeutics (XLO) Enterprise Value (2020 - 2026)
Xilio Therapeutics (XLO) reported Enterprise Value of -$150.3 million for Q1 2026, down 68.74% on a YoY basis from -$480.8 million in Q1 2025, and down 9.28% sequentially from -$137.5 million in Q4 2025.
Xilio Therapeutics (XLO) Enterprise Value (2020 - 2026) Analysis & Trends
Xilio Therapeutics (XLO) has 7 years of Enterprise Value data on file, last reported at -$150.3 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value fell 68.74% year-over-year to -$150.3 million; the trailing twelve-month figure through Mar 2026 stood at -$150.3 million (down 68.74% YoY), and the FY2025 full-year result was -$137.5 million, down 148.74% from the prior year.
- Enterprise Value eased to -$150.3 million in Q1 2026, from -$137.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$34.0 million in Q1 2024 to a low of -$177.0 million in Q1 2022.
- A 5-year average of -$99.8 million and a median of -$93.3 million in 2023 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value surged 63.57% in 2024 and slumped 162.13% in 2025, its largest moves.
- Tracing XLO's Enterprise Value over 5 years: stood at -$120.4 million in 2022, then jumped by 62.87% to -$44.7 million in 2023, then dropped by 23.68% to -$55.3 million in 2024, then tumbled by 148.74% to -$137.5 million in 2025, then retreated by 9.28% to -$150.3 million in 2026.
- Business Quant data shows XLO's Enterprise Value at -$150.3 million in Q1 2026, -$137.5 million in Q4 2025, and -$103.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | -61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.83 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -1.91 Bn |
| 10 | Xilio Therapeutics | 148.60 Mn | -1.70 Mn | - | -150.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -150.30 Mn |
| Dec 31, 2025 | -137.53 Mn |
| Sep 30, 2025 | -103.76 Mn |
| Jun 30, 2025 | -121.55 Mn |
| Mar 31, 2025 | -89.07 Mn |
| Dec 31, 2024 | -55.29 Mn |
| Sep 30, 2024 | -61.26 Mn |
| Jun 30, 2024 | -74.95 Mn |
| Mar 31, 2024 | -33.98 Mn |
| Dec 31, 2023 | -44.70 Mn |
| Sep 30, 2023 | -59.77 Mn |
| Jun 30, 2023 | -75.38 Mn |
| Mar 31, 2023 | -93.27 Mn |
| Dec 31, 2022 | -120.39 Mn |
| Sep 30, 2022 | -139.14 Mn |
| Jun 30, 2022 | -159.41 Mn |
| Mar 31, 2022 | -176.96 Mn |
| Dec 31, 2021 | -198.05 Mn |
| Sep 30, 2021 | -99.77 Mn |
| Jun 30, 2021 | -120.30 Mn |